Fradet Y - Search Results

1

Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma.

Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Jacobson NE, Drachenberg DE, Cagiannos I, So AI, Black PC. Locke JA, et al. Among authors: fradet y. Can Urol Assoc J. 2018 Aug;12(8):243-251. doi: 10.5489/cuaj.5377. Epub 2018 Apr 12. Can Urol Assoc J. 2018. PMID: 29688881 Free PMC article.

2

[Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer].

Lacombe L, Gauthier J, Lafleur L, Fradet Y. Lacombe L, et al. Among authors: fradet y. Prog Urol. 1996 Dec;6(6):907-12. Prog Urol. 1996. PMID: 9235176 French.

3

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.

Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y. Meyer F, et al. Among authors: fradet y. J Urol. 1999 Dec;162(6):2024-8. doi: 10.1016/S0022-5347(05)68092-5. J Urol. 1999. PMID: 10569561 Review.

4

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y. Pfister C, et al. Among authors: fradet y. Hum Pathol. 1999 Nov;30(11):1350-5. doi: 10.1016/s0046-8177(99)90067-9. Hum Pathol. 1999. PMID: 10571516

5

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y. Pfister C, et al. Among authors: fradet y. Clin Cancer Res. 1999 Dec;5(12):4079-84. Clin Cancer Res. 1999. PMID: 10632343

6

Can biological markers predict recurrence and progression of superficial bladder cancer?

Fradet Y, Lacombe L. Fradet Y, et al. Curr Opin Urol. 2000 Sep;10(5):441-5. doi: 10.1097/00042307-200009000-00013. Curr Opin Urol. 2000. PMID: 11005449 Review.

7

Blood management and radical retropubic prostatectomy: Quebec experience.

Lacombe L, Fradet Y. Lacombe L, et al. Among authors: fradet y. Can J Urol. 1999 Apr;6(2):727-731. Can J Urol. 1999. PMID: 11178596

8

Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy.

Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y. Lacombe L, et al. Among authors: fradet y. Int J Cancer. 2001 May 20;95(3):135-9. doi: 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3. Int J Cancer. 2001. PMID: 11307144

9

Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.

Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y. Meyer F, et al. Among authors: fradet y. Urology. 2001 Aug;58(2 Suppl 1):71-7. doi: 10.1016/s0090-4295(01)01245-6. Urology. 2001. PMID: 11502453

10

Prognostic markers in muscle invasive bladder cancer.

Tiguert R, Lessard A, So A, Fradet Y. Tiguert R, et al. Among authors: fradet y. World J Urol. 2002 Aug;20(3):190-5. doi: 10.1007/s00345-002-0279-y. Epub 2002 Jun 7. World J Urol. 2002. PMID: 12196903 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

350 results

Search Page

Filters